Review of heart failure treatment in type 2 diabetes patients: It's at least as effective as in non-diabetic patients!

Diabetes and Metabolism

Volumn 41, Issue 6, 2015, Pages 446-455

  Girerd, N ^a,b,c,d   Zannada, F ^a,b,c,d   Rossignol, P ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d F CRIN INI CRCT (Cardiovascular and Renal Clinical Trialists)   (France)

Author keywords

Absolute treatment effect; Diabetes; Drug optimalization; Heart failure; Treatment

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; IRBESARTAN; IVABRADINE;

ARTICLE; GENERAL PRACTITIONER; HEART FAILURE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RISK; COMPLICATION; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; TREATMENT OUTCOME;

EID: 84939180467     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2015.06.004     Document Type: Review

References (82)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dick-stein K, et al. ESC Guidelines for the diagnosis and treatment of acute andchronic heart failure 2012: The Task Force for the diagnosis and treatmentof acute and chronic heart failure 2012 of the European Society of Cardiol-ogy, developed in collaboration with the Heart Failure Association (HFA)of the ESC. Eur Heart J 2012;33:1787-847.
2. Chen J, Marciniak TA, Radford MJ, Wang Y, Krumholz HM. Beta-blocker therapy for secondary prevention of myocardial infarction in elderlydiabetic patients. Results from the National Cooperative CardiovascularProject. J Am Coll Cardiol 1999;34:1388-94.
3. Ely S. Personalized medicine: individualized care of cancer patients. TranslRes 2009;154:303-8.
4. Damman K, Tang WH, Felker GM, Lassus J, Zannad F, Krum H, et al.Current evidence on treatment of patients with chronic systolic heart failureand renal insufficiency: practical considerations from published data. J AmColl Cardiol 2014;63:853-71.
5. Girerd N, Rossignol P. Personalized ultrafiltration for worsening heart fail-ure: is biological evaluation of plasma volume and lung ultrasound theanswer? Nephrol Ther 2014;10:201-2.
6. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, GaniatsTG, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosisand Management of Heart Failure in Adults: a report of the American Col-lege of Cardiology Foundation/American Heart Association Task Force onPractice Guidelines: developed in collaboration with the International Soci-ety for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
7. Digitalis Investigation Group. The effect of digoxin on mortality and mor-bidity in patients with heart failure. N Engl J Med 1997;336:525-33.
8. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, et al.Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers inthe management of left ventricular systolic dysfunction according to race,gender, and diabetic status: a meta-analysis of major clinical trials. J AmColl Cardiol 2003;41:1529-38.
9. Girerd N, Pibarot P, Daleau P, Voisine P, O'Hara G, Després JP, et al.Statins reduce short- and long-term mortality associated with postoperativeatrial fibrillation after coronary artery bypass grafting: impact of post-operative atrial fibrillation and statin therapy on survival. Clin Cardiol2012;35:430-6.
10. Collier TJ, Pocock SJ, McMurray JJ, Zannad F, Krum H, van VeldhuisenDJ, et al. The impact of eplerenone at different levels of risk in patientswith systolic heart failure and mild symptoms: insight from a novel riskscore for prognosis derived from the EMPHASIS-HF trial. Eur Heart J2013;34:2823-9.
11. Girerd N, Rossignol P, Zannad F. Fibrinolysis for intermediate-risk pul-monary embolism. N Engl J Med 2014;371:579.
12. Girerd N, Magne J, Rabilloud M, Charbonneau E, Mohamadi S, PibarotP, et al. The impact of complete revascularization on long-term survival isstrongly dependent on age. Ann Thorac Surg 2012;94:1166-72.
13. Vaur L, Gueret P, Lievre M, Chabaud S, Passa P, Study DSG. Developmentof congestive heart failure in type 2 diabetic patients with microalbuminuriaor proteinuria: observations from the DIABHYCAR (type 2 DIABetes,Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care2003;26:855-60.
14. Romero SP, Garcia-Egido A, Escobar MA, Andrey JL, Corzo R, PerezV, et al. Impact of new-onset diabetes mellitus and glycemic control onthe prognosis of heart failure patients: a propensity-matched study in thecommunity. Int J Cardiol 2013;167:1206-16.
15. MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvieR, et al. Diabetes, left ventricular systolic dysfunction, and chronic heartfailure. Eur Heart J 2008;29:1224-40.
16. Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious inpatients with diabetes mellitus as in patients without diabetes mellitus whohave chronic heart failure? A meta-analysis of large-scale clinical trials.Am Heart J 2003;146:848-53.
17. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, YoungJB, et al. Impact of diabetes on outcomes in patients with low and preservedejection fraction heart failure: an analysis of the Candesartan in Heartfailure: Assessment of Reduction in Mortality and morbidity (CHARM)programme. Eur Heart J 2008;29:1377-85.
18. The CONSENSUS Trial Study Group. Effects of enalapril on mortal-ity in severe congestive heart failure. Results of the Cooperative NorthScandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med1987;316:1429-35.
19. The SOLVD Investigators. Effect of enalapril on survival in patients withreduced left ventricular ejection fractions and congestive heart failure. NEngl J Med 1991;325:293-302.
20. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown Jr EJ, Cuddy TE,et al. Effect of captopril on mortality and morbidity in patients with leftventricular dysfunction after myocardial infarction. Results of the survivaland ventricular enlargement trial. N Engl J Med 1992;327:669-77.
21. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effectof ramipril on mortality and morbidity of survivors of acute myocar-dial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
22. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H.Effects of the early administration of enalapril on mortality in patientswith acute myocardial infarction. Results of the Cooperative New Scan-dinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med1992;327:678-84.
23. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, et al.Diabetes mellitus, a predictor of morbidity and mortality in the Studies ofLeft Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol1996;77:1017-20.
24. Cohn JN, Tognoni G, Valsartan. Heart Failure Trial I. A randomized trial ofthe angiotensin-receptor blocker valsartan in chronic heart failure. N EnglJ Med 2001;345:1667-75.
25. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al.Randomised trial of losartan versus captopril in patients over 65 withheart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet1997;349:747-52.
26. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ,et al. Effect of losartan compared with captopril on mortality in patientswith symptomatic heart failure: randomised trial-the Losartan Heart FailureSurvival Study ELITE II. Lancet 2000;355:1582-7.
27. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, et al.Candesartan in heart failure-assessment of reduction in mortality and mor-bidity (CHARM): rationale and design. J Card Fail 1999;5:276-82.
28. Carson P, Tognoni G, Cohn JN. Effect of Valsartan on hospitalization:results from Val-HeFT. J Card Fail 2003;9:164-71.
29. Girerd N, Magne J, Pibarot P, Voisine P, Dagenais F, Mathieu P. Post-operative atrial fibrillation predicts long-term survival after aortic-valvesurgery but not after mitral-valve surgery: a retrospective study. BMJ Open2011;1:e000385.
30. Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, et al. EGFRmutations predict survival benefit from gefitinib in patients with advancedlung adenocarcinoma: a historical comparison of patients treated beforeand after gefitinib approval in Japan. J Clin Oncol 2008;26:5589-95.
31. Greenland S. Tests for interaction in epidemiologic studies: a review and astudy of power. Stat Med 1983;2:243-51.
32. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van VeldhuisenDJ, et al. Incidence, determinants, and prognostic significance of hyper-kalemia and worsening renal function in patients with heart failure receivingthe mineralocorticoid receptor antagonist eplerenone or placebo in additionto optimal medical therapy: results from the Eplerenone in Mild PatientsHospitalization and Survival Study in Heart Failure (EMPHASIS-HF). CircHeart Fail 2014;7:51-8.
33. Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J. Predictors ofdecreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of leftventricular dysfunction (SOLVD). Am Heart J 1999;138(5 Pt 1):849-55.
34. CIBIS-II Investigators and Committees. The Cardiac Insuffi-ciency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet1999;353(9146):9-13.
35. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM,et al. The effect of carvedilol on morbidity and mortality in patients withchronic heart failure. N Engl J Med 1996;334:1349-55.
36. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al.Effect of carvedilol on the morbidity of patients with severe chronic heartfailure: results of the carvedilol prospective randomized cumulative sur-vival (COPERNICUS) study. Circulation 2002;106:2194-9.
37. MERIT-HF, Study Group. Effect of metoprolol CR/XL in chronic heartfailure: Metoprolol CR/XL Randomised Intervention Trial in CongestiveHeart Failure (MERIT-HF). Lancet 1999;353:2001-7.
38. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hocanalyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groupswith chronic heart failure. Eur J Heart Fail 2001;3:469-79.
39. Authors/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, CosentinoF, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular dis-eases developed in claboration with the EASD: the Task Force on diabetes,pre-diabetes, and cardiovascular diseases of the European Society of Cardi-ology (ESC) and developed in collaboration with the European Associationfor the Study of Diabetes (EASD). Eur Heart J 2013;34:3035-87.
40. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. Theeffect of spironolactone on morbidity and mortality in patients with severeheart failure. N Engl J Med 1999;341:709-17.
41. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al.Eplerenone, a selective aldosterone blocker, in patients with left ventriculardysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
42. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H,et al. Eplerenone in patients with systolic heart failure and mild symptoms.N Engl J Med 2011;364:11-21.
43. Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H,Pocock SJ, et al. Safety and efficacy of eplerenone in patients at highrisk for hyperkalemia and/or worsening renal function: analyses of theEMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospi-talization And SurvIval Study in Heart Failure). J Am Coll Cardiol2013;62:1585-93.
44. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A,et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a ran-domised placebo-controlled study. Lancet 2010;376:875-85.
45. Digitalis Investigation G. The effect of digoxin on mortality and morbidityin patients with heart failure. N Engl J Med 1997;336:525-33.
46. Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS,et al. Digoxin and reduction in mortality and hospitalization in heart fail-ure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J2006;27:178-86.
47. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino Jr R, Ferdinand K,et al. Combination of isosorbide dinitrate and hydralazine in blacks withheart failure. N Engl J Med 2004;351:2049-57.
48. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, TaylorM, et al. Early and sustained benefit on event-free survival and heartfailure hospitalization from fixed-dose combination of isosorbide dini-trate/hydralazine: consistency across subgroups in the African-AmericanHeart Failure Trial. Circulation 2007;115:1747-53.
49. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al.Prophylactic implantation of a defibrillator in patients with myocardialinfarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
50. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amio-darone or an implantable cardioverter-defibrillator for congestive heartfailure. N Engl J Med 2005;352:225-37.
51. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T,et al. Cardiac-resynchronization therapy with or without an implantabledefibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
52. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, KappenbergerL, et al. The effect of cardiac resynchronization on morbidity and mortalityin heart failure. N Engl J Med 2005;352:1539-49.
53. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP,et al. Cardiac-resynchronization therapy for the prevention of heart-failureevents. N Engl J Med 2009;361:1329-38.
54. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al.Cardiac-resynchronization therapy for mild-to-moderate heart failure. NEngl J Med 2010;363:2385-95.
55. Ghali JK, Boehmer J, Feldman AM, Saxon LA, Demarco T, Carson P,et al. Influence of diabetes on cardiac resynchronization therapy with orwithout defibrillator in patients with advanced heart failure. J Card Fail2007;13:769-73.
56. Hoppe UC, Freemantle N, Cleland JG, Marijianowski M, Erdmann E.Effect of cardiac resynchronization on morbidity and mortality of diabeticpatients with severe heart failure. Diabetes Care 2007;30:722-4.
57. Goldenberg I, Moss AJ, Hall WJ, Foster E, Goldberger JJ, San-tucci P, et al. Predictors of response to cardiac resynchronizationtherapy in the Multicenter Automatic Defibrillator Implantation Trialwith Cardiac Resynchronization Therapy (MADIT-CRT). Circulation2011;124:1527-36.
58. Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiacimplantable electronic device infection: a systematic review and meta-analysis. Europace 2015;17:767-77.
59. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ,et al. Effects of candesartan in patients with chronic heart failure andpreserved left-ventricular ejection fraction: the CHARM-Preserved Trial.Lancet 2003;362:777-81.
60. Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL, öster-gren J, et al. Analysing recurrent hospitalizations in heart failure: a reviewof statistical methodology, with application to CHARM-Preserved. Eur JHeart Fail 2014;16:33-40.
61. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR,et al. Irbesartan in patients with heart failure and preserved ejection fraction.N Engl J Med 2008;359:2456-67.
62. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al.Spironolactone for heart failure with preserved ejection fraction. N Engl JMed 2014;370:1383-92.
63. Rossignol P, Zannad F. Regional differences in heart failure with preservedejection fraction trials: when nephrology meets cardiology but East doesnot meet west. Circulation 2015;131:7-10.
64. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, ClausellN, et al. Regional variation in patients and outcomes in the treatmentof preserved cardiac function heart failure with an aldosterone antagonist(TOPCAT) trial. Circulation 2015;131:34-42.
65. Cohen Solal A, Leurs I, Assyag P, Beauvais F, Clerson P, Contre C, et al.Optimization of heart failure medical treatment after hospital dischargeaccording to left ventricular ejection fraction: the FUTURE survey. ArchCardiovasc Dis 2012;105:355-65.
66. Rossignol P, Zannad F, Pitt B, Writing group of 10th Global Cardio VascularClinical Trialist forum held on December 6th-7th in Paris F. Time to retrievethe best benefits from renin angiotensin aldosterone system (RAAS) inhi-bition in heart failure patients with reduced ejection fraction: lessonsfrom randomized controlled trials and registries. Int J Cardiol 2014;177:731-3.
67. Harjola VP, Follath F, Nieminen MS, Brutsaert D, Dickstein K, DrexlerH, et al. Characteristics, outcomes, and predictors of mortality at 3 monthsand 1 year in patients hospitalized for acute heart failure. Eur J Heart Fail2010;12:239-48.
68. Cleland JG, McDonagh T, Rigby AS, Yassin A, Whittaker T, Dargie HJ.The national heart failure audit for England and Wales 2008-2009. Heart2011;97:876-86.
69. Vorilhon C, Chenaf C, Mulliez A, Pereira B, Clerfond G, Authier N,et al. Heart failure prognosis and management in over-80-year-old patients:data from a French national observational retrospective cohort. Eur J ClinPharmacol 2014;71:251-60.
70. Packer M, Poole-Wilson PA, Armstrong PW, e Cleland JG, HorowitzJD, Massie BM, et al. Comparative effects of low and high doses ofthe angiotensin-converting enzyme inhibitor, lisinopril, on morbidity andmortality in chronic heart failure. Circulation 1999;100:2312-8.
71. Rickli H, Steiner S, Muller K, Hess OM. Betablockers in heart fail-ure: Carvedilol Safety Assessment (CASA 2-trial). Eur J Heart Fail2004;6:761-8.
72. Doughty RN, Wright SP, Pearl A, Walsh HJ, Muncaster S, WhalleyGA, et al. Randomized, controlled trial of integrated heart failure man-agement: the Auckland Heart Failure Management Study. Eur Heart J2002;23:139-46.
73. Driscoll A, Srivastava P, Toia D, Gibcus J, Hare DL. A nurse-led up-titrationclinic improves chronic heart failure optimization of beta-adrenergic recep-tor blocking therapy-a randomized controlled trial. BMC Res Notes2014;7:668.
74. McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, HobbsFD, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heartfailure: putting guidelines into practice. Eur J Heart Fail 2005;7:710-21.
75. http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/Guidelines-Heart-Failure-Web-Tables.pdf
76. Curtis AB, Yancy CW, Albert NM, et al. Cardiac resynchronization ther-apy utilization for heart failure: findings from improve HF. Am Heart J2009;158:956-64.
77. van Veldhuisen DJ, Maass AH, Priori SG, Stolt P, van Gelder IC, Dick-stein K, et al. Implementation of device therapy (cardiac resynchronizationtherapy and implantable cardioverter defibrillator) for patients with heartfailure in Europe: changes from 2004 to 2008. Eur J Heart Fail 2009;11:1143-51.
78. Hernandez AF, Fonarow GC, Liang L, Al-Khatib SM, Curtis LH,LaBresh KA, et al. Sex and racial differences in the use of implantablecardioverter-defibrillators among patients hospitalized with heart failure.JAMA 2007;298:1525-32.
79. Al-Khatib SM, Hellkamp AS, Hernandez AF, Fonarow GC, Thomas KL,Al-Khalidi HR, et al. Trends in use of implantable cardioverter-defibrillatortherapy among patients hospitalized for heart failure: have the previ-ously observed sex and racial disparities changed over time? Circulation2012;125:1094-101.
80. Boriani G, Leyva F. Prophylactic cardioverter defibrillator utilization in the"real world": a conundrum. Int J Cardiol 2012;156:123-4.
81. Arisha MM, Girerd N, Chauveau S, Bresson D, Scridon A, BonnefoyE, et al. In-hospital heart rate turbulence and microvolt T-wave alternansabnormalities for prediction of early life-threatening ventricular arrhyth-mia after acute myocardial infarction. Ann Noninvasive Electrocardiol2013;18:530-7.
82. Gravelin LM, Yuhas J, Remetz M, Radford M, Foley J, Lampert R. Useof a screening tool improves appropriate referral to an electrophysiologistfor implantable cardioverter-defibrillators for primary prevention of suddencardiac death. Circ Cardiovasc Qual Outcomes 2011;4:152-6